Newsbenzinga
Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials
· Published
Article summary
Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $550 million stock offering.
An excerpt from the original article.
Comments —
Loading comments…